GlaxoSmithKline
United States
About GlaxoSmithKline
3039 articles with GlaxoSmithKline
-
Significant and Sustained Drop in Teen and Adult Immunization Rates During Pandemic, Study Shows
6/9/2021
A new claims analysis commissioned by GSK and conducted by Avalere Health, an Inovalon company, showed a sustained drop in immunization rates for recommended vaccines among teens and adults throughout the pandemic in 2020.
-
HIV Epidemic: 40 Years Later
6/4/2021
On June 5, the world marks the 40th anniversary of the HIV epidemic. Biopharma researchers continue to develop safe and effective treatments with an eye to a potential cure. -
AbbVie has been the target of multiple legal inquiries and challenges of its pricing and patent protections. Now, a U.S. senator is taking a gander at the company’s taxes.
-
A two-stage Phase III clinical trial by Sanofi and GSK, is studying a COVID-19 vaccine candidate targeting the original SARS-CoV-2 strain as well as the South African B.1.351 variant.
-
Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate
5/27/2021
Sanofi and GSK started enrollment in their Phase 3 clinical study to assess the safety, efficacy, and immunogenicity of their adjuvanted recombinant-protein COVID-19 vaccine candidate.
-
The company, which isn’t expected to enter the clinic until possibly in 2022, is working to make cell therapies work in solid tumors.
-
GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives Emergency Use Authorization from the US FDA for Treatment of Mild-to-Moderate COVID-19 in High-Risk Adults and Pediatric Patients
5/26/2021
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the U.S. Food and Drug Administration (FDA) granted an Emergency Use Authorization (EUA) for sotrovimab (previously VIR-7831), an investigational single-dose monoclonal antibody, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients
-
When the pandemic hit, many companies diverted resources aimed at HIV to COVID-19, which ended up pausing some research efforts.
-
Clinical Catch-Up: May 17-21
5/24/2021
It was another busy week for clinical trial announcement. Here’s a look. -
GSK said the sale of Innovia stock would help GSK invest in other “strategic priorities,” likely those aimed at plans to separate into two main offerings over the next couple of years.
-
EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology’s Sotrovimab For the Early Treatment of COVID-19
5/21/2021
– Opinion based on the EMA’s Committee for Human Medicinal Products (CHMP) review of available data on sotrovimab (previously VIR-7831) for the early treatment of COVID-19 – – EU member states can use the CHMP positive scientific opinion when making national decisions about the early use of sotrovimab prior to EMA marketing authorization – –
-
Innoviva Announces Strategic Repurchase of GSK’s Equity Stake
5/20/2021
Innoviva to repurchase GSK’s current 32% stake in the company for $392 million
-
X-Vax Technology is preparing to submit an IND application to the U.S. FDA for its experimental vaccine against Herpes simplex virus 1 and 2 (HSV-1 and -2).
-
Temasek has committed $200 million to launch The G2 Bio Companies which focuses on the development of potential next-generation gene therapies.
-
Medicago and GSK announced their positive interim data from a mid-range study of a plant-based vaccine for COVID-19.
-
Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial
5/17/2021
Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adultage groups in Phase 2 trial
-
GSK and Vir Biotechnology Announce the Start of the EMA Rolling Review of VIR-7831 (sotrovimab) for the Early Treatment of COVID-19
5/7/2021
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the European Medicines Agency (EMA) has started a rolling review of data on sotrovimab (previously VIR-7831), an investigational dual-action SARS-CoV-2 monoclonal antibody, for the treatment of adults and adolescents
-
Voltaren Arthritis Pain Gel Empowers Early Morning Risers Living with Osteoarthritis
5/3/2021
GSK Consumer Healthcare, the makers of Voltaren Arthritis Pain Gel revealed new data that uncovers a painful truth: for people with osteoarthritis, mornings can be the most difficult part of the day.
-
BioSpace takes an in-depth look at the Top 25 of Q1.
-
BiologIC Technologies Helps Implement High-throughput Heat Inactivation of Patient Samples at Cambridge Lighthouse Laboratory
4/29/2021
BiologIC Technologies, a pioneer in Industry 4.0 technologies for the bio-revolution, has collaborated with AstraZeneca and Electrolux Professional to implement a high-throughput solution for heat inactivation of patient samples at the Cambridge Lighthouse Laboratory.